Investigating the effectiveness of Difluprednate-Loaded core-shell lipid-polymeric hybrid nanoparticles for ocular delivery

[Display omitted] Uveitis is a sight-threatening disease that causes inflammation in the uvea; difluprednate (DFB) is the first approved drug molecule for postoperative pain, inflammation, and endogenous uveitis. Complex ocular physiology and structure make it difficult to deliver drugs to the eye....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of pharmaceutics 2023-06, Vol.640, p.123006-123006, Article 123006
Hauptverfasser:	Kaviarasi, B., Rajana, Naveen, Pooja, Yeruva Sri, Rajalakshmi, A.N., Singh, Shashi Bala, Mehra, Neelesh Kumar
Format:	Artikel
Sprache:	eng
Schlagworte:	Core-Shell Nanoparticles Delayed-Action Preparations Difluprednate Ex-vivo permeation HET-CAM Humans Hybrid Nanoparticles Inflammation Lipids - chemistry Nanoparticles - chemistry Particle Size Polymers - chemistry Uveitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!